Cargando…
Galectin-3 inhibition using novel inhibitor GR-MD-02 improves survival and immune function while reducing tumor vasculature
Autores principales: | Linch, Stefanie, Kasiewicz, Melissa J, McNamara, Michael, Hilgart, Ian, Farhad, Mohammad, Redmond, William |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649323/ http://dx.doi.org/10.1186/2051-1426-3-S2-P306 |
Ejemplares similares
-
Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T cell anergy and promotes survival in tumor-bearing mice
por: Linch, Stefanie, et al.
Publicado: (2015) -
Combination OX40 agonism/CTLA-4 blockade with vaccination reverses anergy and primes tumor-specific CD8 T cells in mice with spontaneous prostate cancer
por: Linch, Stefanie N, et al.
Publicado: (2013) -
Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity
por: Redmond, William L, et al.
Publicado: (2013) -
Biomarkers of survival statistics (boss) analytical platform
por: McNamara, Michael, et al.
Publicado: (2015) -
Murine peripheral blood prognostic biomarkers for tumor survival following combination aCTLA-4 and aPD-1 treatment
por: Hilgart-Martiszus, Ian, et al.
Publicado: (2015)